,7,8,9 Successful clinical responses to PD-1/PD-L1 blockade are often associated with an increased baseline expression of PD-L1 and preexisting T cell infiltration in the tumor microenvironment (TME).10 The gene discussed is CD274; the disease is neoplasm.